

December 21, 2017

Sumitomo Dainippon Pharma Co., Ltd.
Japan BCG Laboratory
Innovation Network Corporation of Japan

Dissolution of Create Vaccine Company, Ltd.

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada “Sumitomo Dainippon Pharma”), Japan BCG Laboratory (Head Office: Bunkyo-ku, Tokyo; President and CEO: Kazunobu Hayashi “Japan BCG”) and Innovation Network Corporation of Japan (Head Office: Chiyoda-ku, Tokyo; President and COO: Mikihide Katsumata “INCJ”) jointly announce that the three companies have agreed to the dissolution of Create Vaccine Company, Ltd. (Head Office: Osaka, Japan; President: Atsushi Tsuchida “Create Vaccine”), in which they have made a joint investment, as described below.

1. Rationale behind the dissolution

Create Vaccine was established by Sumitomo Dainippon Pharma and Japan BCG for the purposes of developing and marketing novel tuberculosis vaccines, and was jointly invested in by Sumitomo Dainippon Pharma, Japan BCG and INCJ. Since 2013, Create Vaccine has been engaged in joint development of novel tuberculosis vaccines, which incorporated a recombinant human parainfluenza Virus type-2 vector technology, together with the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) and Aeras, a non-profit organization. With the termination of this joint development, Sumitomo Dainippon Pharma, Japan BCG and INCJ have decided to dissolve Create Vaccine.

2. Outline of Create Vaccine Company, Ltd.

(1) Company name	Create Vaccine Company, Ltd.
(2) Address of headquarters	6-8, Doshomachi 2-chome, Chuo-ku, Osaka
(3) Representative	Atsushi Tsuchida (President)
(4) Business description	Research, development, processing, manufacture, sale, and import/export of tuberculosis vaccines
(5) Capital	¥425 million (As of December 21, 2017)
(6) Date Established	July 31, 2013
(7) Major shareholders and shareholding ratio	Sumitomo Dainippon Pharma: 33.40%, Japan BCG : 33.30%, INCJ: 33.30% (As of December 21, 2017)

*A description of joint investment into Create Vaccine Company, Ltd., please refer to the announcement made on May 22, 2014.

3. Timeline

December 2017: Registration of dissolution

December 2017: Commencement of liquidation proceedings

March 2018: Completion of liquidation proceedings (scheduled)

Contacts:

- Sumitomo Dainippon Pharma Co., Ltd. (Public Relations/Investor Relations)
TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)
- Japan BCG Laboratory (Development Planning Dept.)
TEL +81-3-5395-5592
- Innovation Network Corporation of Japan (Corporate Planning Group, Communications)
TEL +81-3-5218-7202